Search
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigational[L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration, similar to the one observed with [lidocaine]. … Both can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks.
Liothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approved[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578] … Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3.
Mixtures: Np Thyroid 90, NP Thyroid 30Categories: Agents used to treat hypothyroidismSemaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. … Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019.
Senescence
go.drugbank.com/conditions/DBCOND0152545Synonyms: (O/E Senile and/or old age) or (senescence) or (senility - no psychosis)Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria.
Rifaximin
go.drugbank.com/drugs/DB01220ApprovedInvestigationalIt is marketed under the brand name Xifaxan by Salix Pharmaceuticals. … Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigational[A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.
Temazepam
go.drugbank.com/drugs/DB00231ApprovedIn particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to … Although the chemical synthesis of temazepam was established by 1965 [A175333], mainstream contemporary use of the medication did not occur until it's legitimate use as treatment for insomnia was accepted
Products: Co Temazepam Capsules 15mg, Co Temazepam Capsules 30mg